Cell and gene therapies offer promise, but face market access challenges

7 November 2017

In light of the progress and potential of cell and gene therapies, Amy Grogg, senior vice president of strategy and communication at US drug wholesale company AmerisourceBergen (NYSE: ABC), considers the strategies needed to overcome challenges around market access and the complexity of commercialization in an expert view column.

Over the next 10 years, the cell and gene therapy pipeline is projected to produce thousands of targeted, potentially curative therapies.

Fueled by medical advances and significant investments in research and development, these personalized therapies – comprised of living cells or genetic materials – could revolutionize how we treat diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK